EMAGINE-Study protocol of a randomized controlled trial for determining the efficacy of a frequency tuned electromagnetic field treatment in facilitating recovery within the subacute phase following ischemic stroke.

Frontiers in neurology · 2023 · Unclear · Insufficient evidence

← Research stream

UnclearInsufficient evidencePaper 5793

Protocol for a multicenter, double-blind, randomized, sham-controlled parallel two-arm trial evaluating safety and efficacy of a non-invasive extremely low-frequency, low-intensity, frequency-tuned electromagnetic field treatment (ENTF) in subacute ischemic s…

Study snapshot

PublicationFrontiers in neurology · 2023

Study typerandomized_trial

Reported directionUnclear

Evidence ratingInsufficient

Abstract

UNLABELLED: Stroke is a leading cause of disability with limited effective interventions that improve recovery in the subacute phase. This protocol aims to evaluate the safety and efficacy of a non-invasive, extremely low-frequency, low-intensity, frequency-tuned electromagnetic field treatment [Electromagnetic Network Targeting Field (ENTF) therapy] in reducing disability and promoting recovery in people with subacute ischemic stroke (IS) with moderate-severe disability and upper extremity (UE) motor impairment. Following a sample-size adaptive design with a single interim analysis, at least 150 and up to 344 participants will be recruited to detect a 0.5-point (with a minimum of 0.33 points) difference on the modified Rankin Scale (mRS) between groups with 80% power at a 5% significance level. This ElectroMAGnetic field Ischemic stroke-Novel subacutE treatment (EMAGINE) trial is a multicenter, double-blind, randomized, sham-controlled, parallel two-arm study to be conducted at approximately 20 United States sites, and enroll participants with subacute IS and moderate-severe disability with UE motor impairment. Participants will be assigned to active (ENTF) or sham treatment, initiated 4-21 days after stroke onset. The intervention, applied to the central nervous system, is designed for suitability in multiple clinical settings and at home. Primary endpoint is change in mRS score from baseline to 90 days post-stroke. Secondary endpoints: change from baseline to 90 days post-stroke on the Fugl-Meyer Assessment - UE (lead secondary endpoint), Box and Block Test, 10-Meter Walk, and others, to be analyzed in a hierarchical manner. EMAGINE will evaluate whether ENTF therapy is safe and effective at reducing disability following subacute IS. TRIAL REGISTRATION: clinicaltrials.gov, NCT05044507 (14 September 2021).

Machine Enhanced Logic

AI evidence extraction

Structured fields below were generated from the paper’s abstract and metadata to make the evidence easier to inspect. Automated extraction may be incomplete or incorrect; verify important details against the original paper.

Study typerandomized_trial

Effect directionunclear

PopulationPeople with subacute ischemic stroke with moderate-severe disability and upper extremity motor impairment

Sample sizeNot supplied

ExposureELF · treatment initiated 4–21 days after stroke onset; outcomes assessed to 90 days post-stroke

Evidence strengthInsufficientConfidence: 78% · Peer reviewed: yes

Main findings

Outcomes measured

Safety
Efficacy
Change in modified Rankin Scale (mRS) from baseline to 90 days post-stroke (primary)
Change in Fugl-Meyer Assessment – Upper Extremity from baseline to 90 days post-stroke (lead secondary)
Change in Box and Block Test from baseline to 90 days post-stroke
Change in 10-Meter Walk from baseline to 90 days post-stroke

Limitations

Study protocol; no outcome results reported
Exposure parameters (e.g., specific frequencies, field strengths) not provided in the abstract

View raw extracted JSON

{
  "study_type": "randomized_trial",
  "exposure": {
    "band": "ELF",
    "source": "therapeutic device (Electromagnetic Network Targeting Field, ENTF)",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "treatment initiated 4–21 days after stroke onset; outcomes assessed to 90 days post-stroke"
  },
  "population": "People with subacute ischemic stroke with moderate-severe disability and upper extremity motor impairment",
  "sample_size": null,
  "outcomes": [
    "Safety",
    "Efficacy",
    "Change in modified Rankin Scale (mRS) from baseline to 90 days post-stroke (primary)",
    "Change in Fugl-Meyer Assessment – Upper Extremity from baseline to 90 days post-stroke (lead secondary)",
    "Change in Box and Block Test from baseline to 90 days post-stroke",
    "Change in 10-Meter Walk from baseline to 90 days post-stroke"
  ],
  "main_findings": "Protocol for a multicenter, double-blind, randomized, sham-controlled parallel two-arm trial evaluating safety and efficacy of a non-invasive extremely low-frequency, low-intensity, frequency-tuned electromagnetic field treatment (ENTF) in subacute ischemic stroke. No results are reported in the abstract.",
  "effect_direction": "unclear",
  "limitations": [
    "Study protocol; no outcome results reported",
    "Exposure parameters (e.g., specific frequencies, field strengths) not provided in the abstract"
  ],
  "evidence_strength": "insufficient",
  "confidence": 0.78,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "ischemic stroke",
    "subacute phase",
    "extremely low-frequency",
    "low-intensity",
    "frequency-tuned electromagnetic field",
    "ENTF therapy",
    "randomized",
    "double-blind",
    "sham-controlled",
    "modified Rankin Scale",
    "Fugl-Meyer Assessment"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract and metadata and may be incomplete or incorrect. This material is for informational purposes and is not medical advice.

Identifiers and source

DOI: 10.3389/fneur.2023.1148074
PubMed: 37213907

Read the original paper →

Related papers

← Back to the Research Library